COMPARATIVE PHARMACOKINETICS AND METABOLISM OF DOXORUBICIN AND EPIRUBICIN IN PATIENTS WITH METASTATIC BREAST-CANCER

被引：0
|
作者：
ROBERT, J [1 ]
VRIGNAUD, P [1 ]
NGUYENNGOC, T [1 ]
ILIADIS, A [1 ]
MAURIAC, L [1 ]
HURTELOUP, P [1 ]
机构：
[1] FAC PHARM MARSEILLE,F-13385 MARSEILLE 4,FRANCE
来源：
CANCER TREATMENT REPORTS | 1985年 / 69卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：633 / 640
页数：8
相关论文
共 50 条
  • [11] A PROSPECTIVE RANDOMIZED COMPARISON OF EPIRUBICIN AND DOXORUBICIN IN PATIENTS WITH ADVANCED BREAST-CANCER
    JAIN, KK
    CASPER, ES
    GELLER, NL
    HAKES, TB
    KAUFMAN, RJ
    CURRIE, V
    SCHWARTZ, W
    CASSIDY, C
    PETRONI, GR
    YOUNG, CW
    WITTES, RE
    JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (06) : 818 - 826
  • [12] PHARMACOKINETICS OF EPI-DOXORUBICIN AND DOXORUBICIN IN BREAST-CANCER PATIENTS - A CROSSOVER STUDY
    MROSS, K
    MAESSEN, P
    VANDERVIJGH, WJF
    GALL, H
    BOVEN, E
    PINEDO, HM
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (01) : 114 - 114
  • [13] TAMOXIFEN CITRATE PHARMACOKINETICS IN PATIENTS WITH METASTATIC BREAST-CANCER
    WILKINSON, P
    RIBEIRO, G
    ADAM, HK
    KEMP, J
    PATTERSON, JS
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 309 - 309
  • [14] MULTIPLE-DOSE PHARMACOKINETICS OF EPIRUBICIN AT 4 DIFFERENT DOSE LEVELS - STUDIES IN PATIENTS WITH METASTATIC BREAST-CANCER
    JAKOBSEN, P
    STEINESS, E
    BASTHOLT, L
    DALMARK, M
    LORENZEN, A
    PETERSEN, D
    GJEDDE, SB
    SANDBERG, E
    ROSE, C
    NIELSEN, OS
    MOURIDSEN, HT
    JAKOBSEN, A
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (01) : 63 - 68
  • [15] PACLITAXEL IN DOXORUBICIN-RESISTANT METASTATIC BREAST-CANCER PATIENTS
    ANAND, A
    ANAND, A
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (21) : 1642 - 1642
  • [16] Alteration in epirubicin pharmacokinetics and metabolism by dexverapamil:: Results from a phase II study in patients with metastatic breast cancer
    Mross, K
    Kröger, N
    Herbst, K
    Gastl, G
    Hossfeld, D
    ONKOLOGIE, 1999, 22 (01): : 35 - 40
  • [17] PROSPECTIVE COMPARISON OF EPIRUBICIN AND DOXORUBICIN IN PREVIOUSLY-TREATED PATIENTS WITH ADVANCED BREAST-CANCER
    YOUNG, C
    WITTES, R
    JAIN, K
    GELLER, N
    CASPER, E
    INVESTIGATIONAL NEW DRUGS, 1984, 2 (01) : 100 - 100
  • [18] EPIRUBICIN AND IFOSFAMIDE IN PATIENTS WITH REFRACTORY BREAST-CANCER AND OTHER METASTATIC SOLID TUMORS
    HOFFMANN, W
    WEIDMANN, B
    MIGEOD, F
    KONNER, J
    SEEBER, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 : S69 - S70
  • [19] LOW-DOSE WEEKLY TREATMENT OF METASTATIC BREAST-CANCER WITH 4'-EPI-DOXORUBICIN (EPIRUBICIN)
    SCHEULEN, ME
    NIEDERLE, N
    DOBERAUER, C
    HOFFKEN, K
    SEIDEL, KJ
    BLUT, 1985, 51 (03): : 195 - 195
  • [20] COMPARATIVE PHARMACOKINETICS OF DOXORUBICIN GIVEN BY 3 DIFFERENT SCHEDULES WITH EQUAL DOSE INTENSITY IN PATIENTS WITH BREAST-CANCER
    TWELVES, CJ
    DOBBS, NA
    ALDHOUS, M
    HARPER, PG
    RUBENS, RD
    RICHARDS, MA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (04) : 302 - 307
12345